Macrocure (NASDAQ: MCUR) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Macrocure to related companies based on the strength of its risk, profitability, valuation, analyst recommendations, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations for Macrocure and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Macrocure 0 0 0 0 N/A
Macrocure Competitors 98 370 970 28 2.63

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.34%. Given Macrocure’s competitors higher possible upside, analysts clearly believe Macrocure has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Macrocure and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Macrocure N/A N/A -0.79
Macrocure Competitors $2.57 billion $977.16 million 2.89

Macrocure’s competitors have higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.8% of Macrocure shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Macrocure has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Macrocure’s competitors have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.

Profitability

This table compares Macrocure and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Macrocure N/A -24.50% -22.85%
Macrocure Competitors -538.85% -41.85% -24.81%

Summary

Macrocure competitors beat Macrocure on 5 of the 8 factors compared.

Macrocure Company Profile

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.